|
Back to Home » June 2018 News » NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics |
NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics |
June 18, 2018
LUND, Sweden and PALO ALTO, Calif., June 18, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under NeuroVive's NVP015 program....
Source URL: https://www.prnewswire.com/news-releases/neurovive-out-licenses-targeted-lhon-therapy-to-bridgebio-pharmas-new-subsidiary-fortify-therapeutics-300667278.html
|
|
|
|
